A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

Neurological Research

Volumn 32, Issue 5, 2010, Pages 451-459

  Collin, Christine ^a   Ehler, E ^a   Waberzinek, G ^a   Alsindi, Z ^a   Davies, P ^a   Powell, K ^a   Notcutt, W ^a   O'leary, C ^a   Ratcliffe, S ^a   Novakova I ^a   Zapletalova, O ^a   Pikova J ^a   Ambler, Z ^a  

^a ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cannabinoids; Multiple sclerosis; Nabiximols; Sativex; Spasticity

Indexed keywords

CANNABIS; PLACEBO; MUSCLE RELAXANT AGENT; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ADULT; ANXIETY; APATHY; ARTICLE; ASTHENIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FEMALE; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; ORGANIC PSYCHOSYNDROME; PARANOIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPASTICITY; URINARY TRACT INFECTION; VERTIGO; XEROSTOMIA; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; MUSCLE SPASTICITY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952835462     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164109X12590518685660     Document Type: Article

References (35)

1. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-595
2. Vukusic S, van Bockstael V, Gosselin S, et al. Regional variations of multiple sclerosis prevalence in French farmers. J Neurol Neurosurg Psychiatry 2007; 78: 707-709
3. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; (4): CD001332
4. Smith CR, La Rocca NG, Giesser BS, et al. High-dose oral baclofen: Experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-1831
5. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: A systematic review. Health Technol Assess 2003; 7: iii, ix-x, 1-111
6. House of Lords Select Committee on Science and Technology. Cannabis: The Scientific and Medical Evidence, Session 1997-1998, 9th Report, London, UK: Her Majesty's Stationary Office, 1998
7. GW Pharma Ltd. Product Monograph SativexH 2005. Available at: http://www.ukcia.org/research/SativexMonograph.pdf
8. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-180
9. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 2000; 5: 37-46
10. Russo EB, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-246
11. Wade D, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo controlled study on 160 patients. Mult Scler 2004; 10: 434-441
12. Collins C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296
13. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: A critical review. Psychol Med 1988; 18: 1007-1019.
14. Farrar JT, Troxel AB, Stott C, et al. Validity, reliability and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post-hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008; 30: 974-985
15. Mahoney FI, Barthel D. Functional evaluation: The Barthel index. Maryland State Med J 1965; 14: 56-61
16. Collin C, Wade DT, Davies S, et al. The Barthel ADL index: A reliability study. Int Disab Study 1998; 10: 61-63
17. Bohannon RW, Smith MB. Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-207
18. Pandyan AD, Johnson GR, Price CI, et al. A review of the properties and limitations of the Ashworth and modified Ashworth scales as measures of spasticity. Clin Rehabil 1999; 13: 373-383
19. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
20. Brooks R. EuroQol: The current state of play. Health Policy 1996; 37: 53-72
21. Dolan P. Modeling valuations for EuroQol health states.Med Care 1997; 35: 1095-1108
22. Vickrey BG, Hays RD, Haaroni R, et al. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187-206
23. Hollis S. Campbell F. What is meant by intention to treat analysis? Survey of published randomized controlled trials. Br Med J 1999; 319: 670-674
24. Kurtzke JF. Rating of neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
25. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404: 84-87
26. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302
27. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-1526
28. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-1669
29. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-29
30. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-645
31. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-424
32. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-819
33. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomized controlled trial. Pain 2004; 112: 299-306
34. Rog DJ, Nurmikko TJ, Young CA. Oral delta 9-tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 9: 2068-2079
35. Nurmikko T, Serpell M, Hoggart B, et al. Sativex successfully treats neuropathic pain characterised by allodynia: A randomized, double-blind, placebo-controlled trial. Pain 2007; 133: 210-220